Skip to main content
Terug
Watch Compare

Allarity Therapeutics, Inc.

Datakwaliteit: 83%
ALLR
Nasdaq Manufacturing Chemicals
€ 1,16
▼ € 0,01 (-0,43%)
Marktkapitalisatie: 18,27 M
Prijs
€ 1,16
Marktkapitalisatie
18,27 M
Dagbereik
€ 1,13 — € 1,18
52-Weeksbereik
€ 0,62 — € 2,35
Volume
41.115
Openen € 1,17
50D / 200D Gem.
€ 1,05
9,56% above
50D / 200D Gem.
€ 1,19
3,23% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -14,83 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-92,90%
Onder sectorgemiddelde (-53,47%)
ROIC-82,37%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,33
Interest Coverage-68,14

Waardering

PE (TTM)
-1,63
Onder sectorgemiddelde (-1,47)
P/B Ratio1,52
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,6 -1,5
P/B 1,5 1,6
ROE % -92,9 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -11,23 M
ROE -92,90% ROA -53,48%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,83 M
ROIC -82,37% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,33
Interest Coverage -68,14 Asset Turnover N/A
Working Capital 11,68 M Tangible Book Value 12,01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,63 Forward P/E N/A
P/B Ratio 1,52 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -81,16%
Market Cap 18,27 M Enterprise Value 1,38 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0,94 OCF / Share -0,94
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 132,03%
SBC-Adj. FCF -15,28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -11,23 M -24,52 M -11,90 M -16,06 M -26,65 M
EPS (Diluted) — — -10,26 -2,21 —
Gross Profit — — -2,27 M — —
Operating Income -12,61 M -27,24 M -17,13 M -34,46 M -26,56 M
EBITDA — — — — —
R&D Expenses 6,60 M 6,10 M 7,10 M 6,93 M 14,20 M
SG&A Expenses — — — — —
D&A — 9.000,0 37.000,0 60.000,0 106.000,0
Interest Expense 185.000,0 653.000,0 498.000,0 12.000,0 93.000,0
Income Tax 0,0 -381.000,0 83.000,0 -1,52 M 133.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18,26 M 22,65 M 11,86 M 14,54 M 49,63 M
Total Liabilities 8,43 M 10,84 M 14,61 M 12,65 M 30,85 M
Shareholders' Equity 9,83 M 11,81 M -2,75 M -113.000,0 18,15 M
Total Debt — 2,69 M — 2,64 M —
Cash & Equivalents 14,69 M 19,53 M 166.000,0 — —
Current Assets 17,93 M 22,34 M 1,97 M 4,97 M 21,05 M
Current Liabilities 8,43 M 10,84 M 14,17 M 11,22 M 20,72 M